30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Biomet

(for fiscal 3Q ended 2/28/14)

$822.5MM, +8%

  • Hips $162.9MM, +4% (U.S. +5%)
  • Knees $254.2MM, +9% (U.S. +8%)
  • Sports Med/Extremities/Trauma (S.E.T.) $169.0MM, +6% (U.S. +10%)
  • Spine, Bone Healing & Microfixation $115.9MM, +17% (U.S. +13%)
  • Dental $64.4MM, +0.3%
  • Cement, Biologics & Other $56.1MM, +6% (U.S. +3%)


  • Acceleration in Europe supported by improvement in hip, knee markets, plus share gains in knee
  • Sales benefit from Lanx partially offset by lower sales due to bracing divestiture, some lower royalties



  • Worldwide hip/knee pure price decreased at low single-digit rate
  • Hips driven by G7 acetabular system, Microplasty, traditional Taperloc Complete stem, Arcos Modular Femoral revision
  • Strong broad-based demand for Vanguard complete, Vanguard SSK 360 revision and Oxford partial knees
  • Oxford growth supported by product/instrument upgrades, DTC campaign, lifetime implant replacement warranty in U.S.
  • >200 surgeons trained on Oxford during quarter
  • Launched Vanguard XP bicruciate preserving knee; commercial launch to commence during 1QFY15



  • 25th consecutive quarter of double-digit growth in extremities
  • Strong demand for JuggerKnot Soft Anchor, Comprehensive Shoulder, DVR Crosslock and ePACK systems
  • Debuted JuggerKnotless soft anchor, launched Signature personalized patient care system for glenoid components


Cement, Biologics & Other

  • Received FDA clearance for Cobalt G antibiotic-loaded cement; will launch in April
  • Launched Stage I shoulder molds, Bonus CC Matrix allograft for use in orthopaedic, spinal, reconstructive, cranio/maxillofacial procedures